Metformin Manufacturing, Supply and Shortage History: What Every Woman Should Know

Why Metformin's Supply Chain Matters Specifically to Women

Women make up a disproportionate share of metformin users. Type 2 diabetes affects women differently than men at every stage of life, and metformin is first-line therapy for both. Beyond diabetes, metformin is the most commonly prescribed medication for polycystic ovary syndrome (PCOS), affecting roughly 8 to 13 percent of women of reproductive age. It is used off-label for insulin resistance in perimenopause, gestational diabetes prevention, and ovulation induction. When supply disruptions hit, women carrying these diagnoses face real clinical risk.

ACOG Practice Bulletin 194 recognizes metformin as an appropriate adjunct for PCOS management, particularly for metabolic features and menstrual irregularity. Women who depend on it for cycle regulation, fertility preparation, or glycemic control during pregnancy need to know what supply instability looks like, what caused it, and how to plan around it.

The Scale of Metformin Use in the United States

Metformin is the most dispensed oral antidiabetic drug in the United States. According to IQVIA data cited by the FDA, it ranks consistently among the top 10 most prescribed medications nationally. Approximately 37 million Americans have type 2 diabetes, and a large share take metformin as their foundation therapy. Add millions more using it for prediabetes and PCOS, and you have a drug where even a modest manufacturing hiccup ripples widely.

How Generic Dominance Shapes Vulnerability

Because metformin went off patent in the United States in 2002, it is manufactured almost exclusively as a generic. Generic manufacturing depends on a concentrated network of active pharmaceutical ingredient (API) suppliers, the majority located in India and China. FDA analysis of the generic drug supply chain has repeatedly flagged this geographic concentration as a structural vulnerability. A single facility problem, a regulatory action, a shipping disruption, or a quality failure can cascade into regional or national shortages faster than most patients expect.

A Brief History of Metformin's Regulatory and Supply Events

Metformin has been available in the United States since FDA approval in 1994. For its first decade on the US market, supply was stable and shortages were rare. The drug's relatively simple chemical structure, biguanide class, kept manufacturing costs low and attracted many generic entrants. That competition was initially protective.

The NDMA Contamination Crisis of 2020

The biggest disruption in metformin's supply history began in May 2020 when the FDA announced it had detected N-nitrosodimethylamine (NDMA) in some extended-release metformin products. NDMA is a probable human carcinogen; the FDA's acceptable daily intake limit is 96 nanograms per day.

The FDA's own laboratory testing found that certain lots of extended-release metformin contained NDMA levels exceeding that threshold, sometimes substantially. Between May and July 2020, the FDA asked several manufacturers to voluntarily recall their extended-release products. Companies that issued recalls included Amneal Pharmaceuticals, Bayshore Pharmaceuticals, Apotex Corp, and others. The full recall list was maintained on the FDA's drug recall database.

Critically, the contamination was limited to extended-release formulations. Immediate-release metformin was not affected. The FDA found that NDMA formed during storage, particularly at higher temperatures, due to a reaction involving the metformin molecule itself and trace impurities. This was a different contamination mechanism than the valsartan and ranitidine NDMA crises, where contamination originated in the manufacturing process.

What the 2020 Recall Meant for Women

For women using extended-release metformin (often preferred because it causes less gastrointestinal distress, which matters especially in pregnancy and with nausea-prone PCOS patients), the recall created a sudden and stressful transition. Prescribers had to switch patients to immediate-release formulations or alternative agents. Women who were pregnant or trying to conceive faced particular anxiety, given uncertainty about cumulative NDMA exposure.

FDA guidance at the time recommended that patients not stop metformin without talking to their provider, because uncontrolled blood glucose carries its own risks, including in pregnancy. That recommendation remains sound.

Shortage History Before and After 2020

Before 2020, metformin experienced sporadic but minor shortages. The FDA drug shortage database shows several episodes from 2010 to 2019, most tied to manufacturing capacity issues at specific facilities rather than API unavailability. These resolved within weeks to a few months.

After the 2020 extended-release recalls, a secondary shortage developed as demand shifted to immediate-release tablets faster than the supply chain could accommodate. Pharmacies in some regions reported allocation limits. Women who called multiple pharmacies for their prescription were not experiencing hypochondria; they were navigating a real, documented supply constraint.

The pattern across these events reveals a framework for understanding metformin supply risk: contamination-driven recalls create rapid demand shifts to unaffected formulations, which then become the new shortage point. Planning for this requires knowing which formulation you take, whether your pharmacy stocks alternatives, and what your prescriber's backup plan is.

How Metformin Is Manufactured: From API to Tablet

Understanding why shortages happen requires a basic map of how metformin moves from raw chemistry to your pharmacy shelf.

Active Pharmaceutical Ingredient Production

Metformin's API, metformin hydrochloride, is synthesized from dimethylamine and 2-cyanoguanidine (dicyandiamide). It is chemically uncomplicated relative to most modern drugs, but scale and consistency matter. The bulk of global API production is concentrated in a small number of facilities in India (particularly Gujarat and Maharashtra) and China. FDA inspections of foreign API facilities have found GMP deficiencies at multiple sites over the past decade, leading to import alerts that temporarily remove a supplier from the US market.

Finished Dose Manufacturing

API is shipped to finished dose manufacturers, who blend it with excipients, compress it into tablets, coat them, and package them. In the US market, major finished-dose manufacturers include Amneal Pharmaceuticals, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Lupin, and Aurobindo Pharma. Most of these companies source API internationally. A disruption at a single API supplier can affect multiple US-branded generics simultaneously, which is why shortages can feel sudden and broad.

Extended-Release vs. Immediate-Release Manufacturing Complexity

Extended-release metformin (ER or XR) uses polymer matrix technology to slow drug release over 12 to 24 hours. This manufacturing is more complex than immediate-release tablets. ER tablets require tighter control of the polymer coating and tablet matrix composition. The 2020 NDMA finding was linked in part to specific polymer systems and storage conditions. Because ER requires more specialized manufacturing lines, fewer facilities produce it, making supply more fragile when a recall hits.

Metformin's Mechanism of Action: Why It Works Differently in Women

Metformin's core mechanism is suppression of hepatic glucose production, primarily through inhibition of mitochondrial complex I. This reduces gluconeogenesis and glycogenolysis in the liver. Secondary mechanisms include improved peripheral insulin sensitivity, modest reductions in intestinal glucose absorption, and effects on the gut microbiome that may contribute independently to glycemic benefit. The UKPDS 34 trial demonstrated a 32 percent reduction in any diabetes-related endpoint compared with conventional therapy in overweight patients with type 2 diabetes, establishing metformin as a cornerstone therapy.

Sex-Specific Pharmacokinetics

Women absorb and clear metformin differently than men, though these differences are often underemphasized in standard prescribing guides. Pharmacokinetic studies in women show that metformin's volume of distribution is lower in women, and plasma concentrations tend to run higher at equivalent weight-based doses. Renal clearance of metformin, which is the primary elimination route, correlates with glomerular filtration rate, and GFR interpretation differs between sexes. A serum creatinine that looks acceptable by standard thresholds may reflect a meaningfully lower GFR in a small-framed woman than in a larger man.

This matters clinically: women may need lower doses to achieve equivalent glycemic control with fewer GI side effects, and the threshold for dose reduction in renal impairment should be interpreted using an eGFR formula (such as CKD-EPI) rather than raw creatinine.

Hormonal Influences Across the Cycle and Life Stages

Reproductive Years and PCOS

Insulin resistance worsens in the luteal phase of the menstrual cycle, driven by progesterone. Women with PCOS have amplified baseline insulin resistance, making metformin's hepatic effects particularly relevant. ASRM guidelines note that metformin improves menstrual regularity and reduces androgen levels in PCOS, though it is not a primary fertility treatment. For ovulation induction, it is often used in combination with clomiphene or letrozole.

Perimenopause

As estrogen declines in perimenopause, insulin sensitivity worsens and visceral fat increases even in women who have not previously had metabolic disease. Women who were managing blood glucose adequately on lower-dose metformin may find their control deteriorating in their late 40s or early 50s without any change in diet or activity. A dose review at this life stage is appropriate. There are no specific metformin trials conducted in perimenopausal women as a defined population; evidence at this stage is extrapolated from broader type 2 diabetes and prediabetes trials. That evidence gap is real and should be named openly.

Postpartum

Insulin sensitivity improves sharply after delivery. Women who took metformin throughout pregnancy may need dose reduction in the postpartum period to avoid hypoglycemia, particularly if they are breastfeeding (see lactation section below). Postpartum thyroiditis, which affects approximately 5 to 10 percent of postpartum women, can also transiently alter glucose metabolism and should be considered if glycemic patterns shift unexpectedly.

Pregnancy, Lactation, and Contraception: The Full Picture

Pregnancy Safety

Metformin is not formally FDA-approved for use in pregnancy. It carries no official FDA pregnancy category under the current labeling system (the old letter categories were retired in 2015), but human data exists and is more reassuring than for many drugs used in pregnancy.

The MiG trial (Metformin in Gestational Diabetes), published in the New England Journal of Medicine in 2008, randomized 751 women with gestational diabetes to metformin or insulin. Metformin was not associated with increased perinatal complications, and women in the metformin group had less weight gain. However, 46 percent required supplemental insulin, which is a number worth knowing before choosing this route.

For women with type 2 diabetes, many endocrinologists and maternal-fetal medicine specialists continue metformin through the first trimester while transitioning to insulin for optimal second and third trimester glycemic control. ACOG Practice Bulletin 201 supports individualized decisions. For PCOS, some clinicians continue metformin through the first trimester to reduce early pregnancy loss risk, though evidence for this specific benefit is mixed and should not be overstated.

Metformin crosses the placenta freely. Long-term follow-up data from MiG offspring at age 2 showed no difference in height, weight, or motor-social development, but nine-year follow-up data suggested metformin-exposed children had higher body fat and larger waist circumference, raising questions that have not yet been fully resolved. Women who are pregnant or planning pregnancy should have this conversation explicitly with their provider rather than assuming continuation is automatically safe.

Lactation

Metformin transfers into breast milk in small amounts. Studies measuring metformin in breast milk find infant dose estimates below 0.5 percent of the maternal weight-adjusted dose, which is generally considered low risk. No adverse effects in breastfed infants have been reported in published case series. The LactMed database maintained by NIH classifies maternal metformin use as probably compatible with breastfeeding.

Monitoring infant blood glucose is reasonable but not universally required; the clinical decision should be individualized.

Contraception Considerations

Metformin is not a teratogen in the same category as drugs that require mandatory contraception (such as isotretinoin or valproate). Women of reproductive age taking metformin for PCOS or diabetes do not need a specific contraception program mandated by the drug itself. However, because metformin can restore ovulation in women with PCOS who previously thought they were anovulatory, an unintended pregnancy risk may increase when starting metformin. Women who are not trying to conceive should use reliable contraception when beginning metformin for PCOS.

Who Metformin Is Right For (and Who It Is Not)

Life-Stage and Condition Fit

Metformin is well matched to:

• Women with type 2 diabetes at any reproductive life stage, as first-line therapy alongside lifestyle change
• Women with prediabetes and additional metabolic risk factors (PCOS, obesity, family history), where the Diabetes Prevention Program showed metformin reduced diabetes incidence by 31 percent in high-risk adults
• Women with PCOS who have metabolic features, irregular cycles not responding to lifestyle alone, or who are preparing for ovulation induction
• Women with type 2 diabetes who are trying to conceive, in consultation with maternal-fetal medicine

Metformin is NOT appropriate for:

• Women with eGFR below 30 mL/min/1.73m2 (contraindicated due to lactic acidosis risk)
• Women with active hepatic impairment (impairs lactate clearance)
• Women scheduled for iodinated contrast procedures (hold 48 hours before and after if eGFR is 30 to 60)
• Women with type 1 diabetes as a substitute for insulin

The GI Side Effect Reality for Women

Gastrointestinal side effects (nausea, diarrhea, bloating) occur in up to 30 percent of patients starting immediate-release metformin. Women with PCOS who already experience GI symptoms, or pregnant women with nausea, may find immediate-release metformin particularly difficult to tolerate. Starting at 500 mg once daily with dinner and titrating slowly over four to eight weeks reduces dropout rates significantly. Extended-release formulations, when available, cause substantially less GI distress, which is precisely why their absence during the 2020 recall was so new for women who had switched to ER for tolerability reasons.

What to Do During a Metformin Shortage

If you cannot fill your metformin prescription, do not simply stop. Abrupt discontinuation risks rapid glycemic deterioration, particularly in women with type 2 diabetes.

Practical steps:

1. Call multiple pharmacies. Shortages are frequently regional and one pharmacy may have stock when another does not.
2. Ask your prescriber whether switching from ER to IR (or vice versa) is clinically appropriate. Doses are not always directly equivalent on a milligram basis; your prescriber should confirm the switch.
3. Check the FDA drug shortage database to understand whether the shortage is national or localized.
4. For women with type 2 diabetes, your prescriber may need to bridge with an alternative agent such as an SGLT2 inhibitor or GLP-1 receptor agonist. These have different cost and insurance profiles.
5. For women using metformin only for PCOS-related cycle regulation, discuss with your provider which effects are most time-sensitive. Missing one to two months is less immediately dangerous than missing it in the context of active diabetes management or IVF preparation.

As WomanRx clinical reviewer Dr. Elena Vasquez notes: "When a metformin shortage hits, the women I worry about most are those using it for PCOS who have just started seeing regular cycles. They often don't realize how quickly their cycle can revert, and they may not know to call their provider because they think of it as a diabetes drug that doesn't apply urgently to them. It does. Call your provider the day you can't fill your prescription, not after three missed cycles."

Monitoring and Long-Term Safety Considerations for Women

Vitamin B12 Depletion

Long-term metformin use reduces vitamin B12 absorption in approximately 10 to 30 percent of patients, through impaired intrinsic factor-independent absorption in the terminal ileum. Women with already low B12 (common in vegetarians, vegans, and women who have had bariatric surgery) are at higher risk. Annual B12 monitoring is recommended for women on long-term metformin. B12 deficiency can cause peripheral neuropathy and, in pregnancy, neural tube defects. This is an underrecognized risk that deserves a direct conversation.

Renal Monitoring

Because metformin is renally cleared and contraindicated with low eGFR, annual renal function checks are standard. In women, renal function can decline acutely with dehydration (common during hyperemesis gravidarum or illness), and creatinine-based eGFR may be less accurate at extremes of muscle mass. Using CKD-EPI rather than MDRD improves accuracy in women and in older individuals.

Thyroid Interactions

Metformin may lower TSH levels independent of changes in thyroid hormone concentrations, a finding documented in observational studies in euthyroid patients. Women on thyroid replacement therapy who start or stop metformin may notice TSH drift. This is not a contraindication, but thyroid function should be rechecked within three to six months of any significant metformin dose change in women on levothyroxine. Postpartum thyroiditis, already a watchpoint in the first year after delivery, adds another reason to monitor thyroid function alongside metformin in that period.